SAN DIEGO, Aug. 3, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the second quarter 2015 on Monday, August 10, 2015 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date post-market, Halozyme will release financial results for
the second quarter 2015.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the call. To access the webcast and additional documents
related to the call, please log on to halozyme.com approximately
fifteen minutes prior to the call to register, download and install
any necessary audio software. The live call may be accessed by
calling (866) 710-0179 (domestic callers) or (334) 323-7224
(international callers) using passcode 769890. A telephone replay
will be available after the call by dialing (877) 919-4059
(domestic callers) or (334) 323-0140 (international callers) using
replay ID number 53958140.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, metastatic breast
cancer and has potential across additional cancers in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug
delivery platform, ENHANZE™, which enables biologics and small
molecule compounds that are currently administered intravenously to
be delivered subcutaneously. Halozyme is also pursuing clinical
collaborations with biopharmaceutical companies including Eisai, to
evaluate the pan-tumor potential of PEGPH20. Halozyme is
headquartered in San Diego. For
more information visit halozyme.com.
Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-host-second-quarter-2015-financial-results-conference-call-300122693.html
SOURCE Halozyme Therapeutics, Inc.